The INSIGHT-MM Study

To learn more about INSIGHT-MM, please visit https://clinicaltrials.gov/ct2/show/study/NCT02761187.

Despite Clinical Advances, Many Questions Remain Unanswered

Multiple myeloma is the second most common hematologic malignancy, with a worldwide incidence of an estimated 114,000 new cases per year.1 The treatment landscape for patients with multiple myeloma has changed drastically in the past decade. Despite these clinical advances, many questions remain unanswered, and there is a need to advance understanding of real-world experience with therapies and clinical outcomes in patients with multiple myeloma.

Global Observational Study for Multiple Myeloma

In March 2016, Takeda initiated a non-interventional, observational and longitudinal study to track patterns and advance understanding of real-world experience with therapies and clinical outcomes in patients with newly diagnosed and relapsed/refractory multiple myeloma.

The INSIGHT-MM study will be the largest pharmaceutical company-sponsored study of its kind in multiple myeloma, with the goal to enroll a minimum of 5,000 patients 18 years or older with newly diagnosed or relapsed/refractory multiple myeloma globally. Data will be gathered via routine office visits, medical records and patient self-reported outcomes. The INSIGHT-MM study will be led by a steering committee of myeloma experts. The study plans to enroll patients at more than 150 study sites in 15 countries across Asia, Europe, Middle East, South America and North America.

For more information about INSIGHT-MM, visit https://clinicaltrials.gov/ct2/show/study/NCT02761187.
Study Number: NSMM-5001

1 International Agency for Research on Cancer. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality, and Prevalence Worldwide in 2012. Available at http://globocan.iarc.fr/Pages/fact_sheets_population.aspx. Accessed July 2016.